Autoimmune (AI) disorders like rheumatoid arthritis (RA) and systemic lupus erythmatosus (SLE) afflict 1 in 50 Americans and cost more than $100B annually. A hallmark of autoimmunity is recognition and binding to self- antigens by host B cell/T cell receptors (BCR/TCR) resulting in cycles of host cell apoptosis and inflammation. To date, there are few druggable targets for treatment of autoimmunity. Instead, clinicians use broadly immunosuppressant antibodies that indiscriminately target all B cells in an effort to inhibit those that bind self-antigen peptides (SAP). This results in significant collateral damage because most B cells are a healthy component of the immune system. The ideal treatment for autoimmune disorders would specifically target autoimmunogenic B cells while leaving the healthy cells unscathed;however, identifying these cells is extremely challenging because it requires knowledge of the autoimmunogenic BCR sequences and the self- antigens they bind. To address this unmet need, I will develop microfluidic autoimmunoprofiling (MAP), a methodology that will enable the discovery of autoimmunogenic BCRs and the self-antigens they bind. The MAP process will leverage recent developments from my lab in performing PCR reactions on single cells in microfluidic drops, which is a critical step in the workflow that is ued to covalently link the sequence of phage expressing self-peptides to the variable region of the heavy chain of the BCR that binds that self- antigen. Previous attempts at performing PCR on individual mammalian cells in microdroplets failed because mammalian cell lysate is a potent inhibitor of PCR, particularly when contained in picoliter volumes. To overcome inhibition, my lab developed a microfluidic workflow that treats cell lysate using detergents and protease digestion, dilutes it to workable concentrations, and then injects PCR reagent after the proteases are heat-inactivated;these essential steps are all performed while maintaining the compartmentalization of the droplets and keeping the RNA and genomes of individual cells segregated from one another. Moreover, as we have shown, this methodology is ultrahigh-throughput, allowing millions of cells to be subjected to single cell droplet PCR. The ultrahigh-throughput is critical for MAP because it is the enabling feature that will allow us to screen the entire self-antigen peptide/BCR space of binding interactions and capture all interactions. With MAP, we will be able to analyze an autoimmune patient's repertoire to uncover all self-antigens recognized by antibodies in the repertoire, and the specific antibodies that are responsible for this recognition. In addition, using PCR-activated cell sorting, another technology developed by my lab, we will be able purify the autoimmunogenic B cells out of the repertoire to subject them to individual transcriptome analysis. This may ultimately allow us to identify biomarkers unique to this disease-causing cell population and, potentially, identify new ways to specifically inhibit them, thereby treating the disease with fewer side effects. This project should therefore broadly impact our ability to understand the fundamental biology of autoimmunity while also enabling new diagnostics and targeted, personalized therapies.

Public Health Relevance

Autoreactive B cells play a central role in autoimmune disorders, but there is no effective way to detect and recover these cells for isolated analysis. Using a new microfluidic autoimmunoprofiling method, we will detect these cells in patient blood and recover them isolated analysis. By studying these cells in isolation we will be able to identif differences in the biology of these and healthy cells and potentially discover new mechanisms leading to the breakdown of immunological tolerance. This will enable a deeper understanding autoimmunity and may pave the way for new diagnostics and personalized autoimmune therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
NIH Director’s New Innovator Awards (DP2)
Project #
1DP2AR068129-01
Application #
8757740
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Wang, Yan Z
Project Start
2014-09-30
Project End
2019-06-30
Budget Start
2014-09-30
Budget End
2019-06-30
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Siltanen, Christian A; Cole, Russell H; Poust, Sean et al. (2018) An Oil-Free Picodrop Bioassay Platform for Synthetic Biology. Sci Rep 8:7913
Hatori, Makiko N; Kim, Samuel C; Abate, Adam R (2018) Particle-Templated Emulsification for Microfluidics-Free Digital Biology. Anal Chem 90:9813-9820
Delley, Cyrille L; Liu, Leqian; Sarhan, Maen F et al. (2018) Combined aptamer and transcriptome sequencing of single cells. Sci Rep 8:2919
Kim, Samuel C; Clark, Iain C; Shahi, Payam et al. (2018) Single-Cell RT-PCR in Microfluidic Droplets with Integrated Chemical Lysis. Anal Chem 90:1273-1279
Demaree, Benjamin; Weisgerber, Daniel; Lan, Freeman et al. (2018) An Ultrahigh-throughput Microfluidic Platform for Single-cell Genome Sequencing. J Vis Exp :
Lan, Freeman; Demaree, Benjamin; Ahmed, Noorsher et al. (2017) Single-cell genome sequencing at ultra-high-throughput with microfluidic droplet barcoding. Nat Biotechnol 35:640-646
Karbaschi, Mohsen; Shahi, Payam; Abate, Adam R (2017) Rapid, chemical-free breaking of microfluidic emulsions with a hand-held antistatic gun. Biomicrofluidics 11:044107
Sukovich, David J; Kim, Samuel C; Ahmed, Noorsher et al. (2017) Bulk double emulsification for flow cytometric analysis of microfluidic droplets. Analyst 142:4618-4622
Sukovich, David J; Lance, Shea T; Abate, Adam R (2017) Sequence specific sorting of DNA molecules with FACS using 3dPCR. Sci Rep 7:39385
Shahi, Payam; Kim, Samuel C; Haliburton, John R et al. (2017) Abseq: Ultrahigh-throughput single cell protein profiling with droplet microfluidic barcoding. Sci Rep 7:44447

Showing the most recent 10 out of 27 publications